Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis

Clinical Infectious Diseases

Volumn 45, Issue 5, 2007, Pages 562-568

  Catanzaro, Antonino ^a   Cloud, Gretchen A ^g   Stevens, David A ^b,c   Levine, Bernard E ⁱ   Williams, Paul L ^d   Johnson, Royce H ^e   Rendon, Adrian ^k   Mirels, Laurence F ^b,c   Lutz, Jon E ^f   Holloway, Melissa ^h   Galgiani, John N ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Visalia Medical Clinic   (United States)

^e KERN MEDICAL CENTER   (United States)

^f Saint Agnes Medical Center   (United States)

^g University of Alabama at Birmingham   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ Pulmonary Associates   (United States)

^j SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^k HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COCCIDIOIDES; COCCIDIOIDOMYCOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; SKIN NODULE; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; AGED; ANTIBIOTICS, ANTIFUNGAL; COCCIDIOIDOMYCOSIS; FEMALE; HUMANS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIAZOLES;

EID: 34548222507     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519937     Document Type: Article

References (27)

1. Drutz DJ, Catanzaro A. Coccidioidomycosis. I. Am Rev Respir Dis 1978; 117:559-85.
2. Stevens DA. Coccidioidomycosis. N Engl J Med 1995; 332:1077-82.
3. Drutz DJ, Catanzaro A. Coccidioidomycosis. II. Am Rev Respir Dis 1978; 117:727-71.
4. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217-23.
5. Drutz DJ. Amphotericin B in the treatment of coccidioidomycosis. Drugs 1983; 26:337-46.
6. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49(Suppl 1):37-41.
7. Catanzaro A, Einstein H, Levine B, et al. Ketoconazole for treatment of disseminated coccidioidomycosis. Ann Intern Med 1982; 96:436-40.
8. Tucker RM, Denning DW, Arathoon EG, Rinaldi MG, Stevens DA. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990; 23:593-601.
9. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Ann Intern Med 2000; 133:676-86.
10. Catanzaro A, Galgiani JN, Levine BE, et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 1995; 98:249-56.
11. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009-15.
12. Gonzalez GM, Tijerina R, Najvar LK, et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 2002; 46:1352-6.
13. Lutz JE, Clemons KV, Aristizabal BH, Stevens DA. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 1997; 41:1558-61.
14. Noxafil (posaconazole) 40 mg/mL oral suspension [summary of product characteristics]. Brussels, Belgium: Schering-Plough Europe, 2006.
15. Kim H, Kumari P, Laughlin M, et al. Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma. J Chromatogr A 2003; 987:243-8.
16. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M. In vitro antifungal activity of micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms. Antimicrob Agents Chemother 2003; 47:1376-81.
17. Kamberi P, Sobel RA, Clemons KV, et al. Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis. Antimicrob Agents Chemother 2007; 51:998-1003.
18. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47:2788-95.
19. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50:658-66.
20. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12.
21. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
22. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47.
23. Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007 [Epub ahead of print].
24. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42:1726-34.
25. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003; 57:218-22.
26. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50:658-66.
27. Galgiani JN, Stevens DA, Graybill JR, Dismukes WE, Cloud GA. Ketoconazole therapy of progressive coccidioidomycosis: comparison of 400- and 800-mg doses and observations at higher doses. Am J Med 1988; 84:603-10.